重大事件
外國發行人報告
6-K
2026-06-22
Galmed Pharmaceuticals提交6-K 附重要協議及兩份新聞稿
AI 繁中摘要
Galmed Pharmaceuticals Ltd.（以色列製藥公司，納斯達克代碼：GLMD）於2026年6月22日向美國SEC提交6-K表格，報告日期為同日。是次申報附有多份展示文件，包括一份重要協議（EX-10.1）及兩份新聞稿（EX-99.1及EX-99.2），內容可能涉及公司臨床進展、合作或融資安排。由於輸入未提供具體事件
展開英文正文
EDGAR Filing Documents for 0001493152-26-029478 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001493152-26-029478 Filing Date 2026-06-22 Accepted 2026-06-22 07:00:12 Documents 5 Period of Report 2026-06-22 Document Format Files Seq Description Document Type Size 1 6-K form6-k.htm 6-K 27247 2 EX-10.1 ex10-1.htm EX-10.1 632322 3 EX-99.1 ex99-1.htm EX-99.1 102532 4 EX-99.2 ex99-2.htm EX-99.2 22128 5 GRAPHIC ex99-2_001.jpg GRAPHIC 8720 Complete submission text file 0001493152-26-029478.txt 797487 Mailing Address C/O MEITAR LAW OFFICES 16 ABBA HILLEL SILVER RD. RAMAT GAN L3 5250608 Business Address C/O MEITAR LAW OFFICES 16 ABBA HILLEL SILVER RD. RAMAT GAN L3 5250608 97236938448 Galmed Pharmaceuticals Ltd. (Filer) CIK: 0001595353 (see all company filings) EIN.: 981147233 | State of Incorp.: L3 | Fiscal Year End: 1231 Type: 6-K | Act: 34 | File No.: 001-36345 | Film No.: 261104868 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)